Monatsschrift Kinderheilkunde

, Volume 163, Issue 2, pp 135–141 | Cite as

Wachstum und Knochenstoffwechsel nach onkologischer Erkrankung im Kindes- und Jugendalter

Leitthema
First Online:
  • 184 Downloads

Zusammenfassung

Die S3-Leitlinie „Endokrinologische Nachsorge nach onkologischen Erkrankungen im Kindes- und Jugendalter“ enthält Empfehlungen zur regelmäßigen Nachsorge dieser Patienten. Der Schwerpunkt der vorliegenden Arbeit liegt auf der Erfassung möglicher Störungen des Körperhöhenwachstums und des Knochenstoffwechsels. Die Beurteilung des Wachstums hat besonderes Gewicht, sind doch verschiedenste Faktoren (Hormone, Ernährungszustand, intakte Organfunktionen, insbesondere von Leber, Nieren, Herz und Lungen) für ein altersgerechtes Körperhöhenwachstum erforderlich. Das Skelettsystem kann unter onkologischen Therapien geschädigt werden. Regelmäßige Untersuchungen sollten u. a. das Auftreten von pathologischen Frakturen, Fehlstellungen der (unteren) Extremitäten und einer sekundären Osteoporose verhindern.

Schlüsselwörter

Wachstumsfaktorenmangel Hypophyseninsuffizienz Wachstumsstörung Rachitis Osteoporose 

Growth and bone metabolism after oncological disease in childhood and adolescence

Abstract

The clinical guidelines (S3) for endocrine follow-up after pediatric oncological disease provides recommendations for structured follow-up care of these patients. This article focuses on possible late effects interfering with growth and bone metabolism. The assessment of growth is of special importance after pediatric oncological disease. Several factors, such as hormones, nutritional status and integrity of organ function, especially of the liver, kidneys, heart and lungs have a significant impact on growth. Oncological disease and therapy have potential adverse effects on the skeletal system. Regular follow-up monitoring is recommended for early detection and prevention of pathological fractures, bone deformities especially of the lower extremities and secondary osteoporosis.

Keywords

Growth hormone deficiency Hypopituitarism Growth disorders Rickets Osteoporosis 
This is a preview of subscription content, log in to check access.

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. H.L. Müller, T. Langer und D. Schnabel geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Aisenberg J, Hsieh K, Kalaitzoglou G et al (1998) Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 20:241–245CrossRefPubMedGoogle Scholar
  2. 2.
    Birkebaek NH, Fisker S, Clausen N et al (1998) Growth and endocrinological disorders up to 21 years after treatment for acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 30:351–356CrossRefPubMedGoogle Scholar
  3. 3.
    Canalis E (1996) Clinical review 83: mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:3441–3447PubMedGoogle Scholar
  4. 4.
    Clayton PE, Price DA, Shalet SM et al (1988) Craniopharyngioma recurrence and growth hormone therapy. Lancet 1:642CrossRefPubMedGoogle Scholar
  5. 5.
    Clayton PE, Shalet SM (1991) Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 118:226–228CrossRefPubMedGoogle Scholar
  6. 6.
    Clayton PE, Shalet SM, Gattamaneni HR et al (1987) Does growth hormone cause relapse of brain tumours? Lancet 1:711–713CrossRefPubMedGoogle Scholar
  7. 7.
    Clayton PE, Shalet SM, Morris-Jones PH et al (1988) Growth in children treated for acute lymphoblastic leukaemia. Lancet 1:460–462CrossRefPubMedGoogle Scholar
  8. 8.
    Clayton PE, Shalet SM, Price DA et al (1989) Ovarian function following chemotherapy for childhood brain tumours. Med Pediatr Oncol 17:92–96CrossRefPubMedGoogle Scholar
  9. 9.
    Denzer C, Brabant G, Brämswig J et al (2014) Endokrinologische Nachsorge nach onkologischen Erkrankungen im Kindes- und Jugendalter. AWMF-Register Nr. 025-030. http://www.awmf.orgGoogle Scholar
  10. 10.
    Devile CJ, Grant DB, Hayward RD et al (1996) Growth and endocrine sequelae of craniopharyngioma. Arch Dis Child 75:108–114CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Ergun-Longmire B, Mertens AC, Mitby P et al (2006) Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 91:3494–3498CrossRefPubMedGoogle Scholar
  12. 12.
    Fan C, Foster BK, Wallace WH et al (2011) Pathobiology and prevention of cancer chemotherapy-induced bone growth arrest, bone loss, and osteonecrosis. Curr Mol Med 11:140–151CrossRefPubMedGoogle Scholar
  13. 13.
    Follin C, Thilen U, Ahren B et al (2006) Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab 91:1872–1875CrossRefPubMedGoogle Scholar
  14. 14.
    Holm K, Nysom K, Rasmussen MH et al (1996) Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency. Bone Marrow Transplant 18:163–170PubMedGoogle Scholar
  15. 15.
    Land C, Schoenau E (2008) Fetal and postnatal bone development: reviewing the role of mechanical stimuli and nutrition. Best Pract Res Clin Endocrinol Metab 22:107–118CrossRefPubMedGoogle Scholar
  16. 16.
    Loebstein R, Atanackovic G, Bishai R et al (1999) Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39:454–461PubMedGoogle Scholar
  17. 17.
    Oberfield SE, Soranno D, Nirenberg A et al (1996) Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediatr Adolesc Med 150:589–592CrossRefPubMedGoogle Scholar
  18. 18.
    Ogilvy-Stuart AL, Clayton PE, Shalet SM (1994) Cranial irradiation and early puberty. J Clin Endocrinol Metab 78:1282–1286PubMedGoogle Scholar
  19. 19.
    Packer RJ, Boyett JM, Janss AJ et al (2001) Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 19:480–487PubMedGoogle Scholar
  20. 20.
    Price DA, Wilton P, Jonsson P et al (1998) Efficacy and safety of growth hormone treatment in children with prior craniopharyngioma: an analysis of the Pharmacia and Upjohn International Growth Database (KIGS) from 1988 to 1996. Horm Res 49:91–97CrossRefPubMedGoogle Scholar
  21. 21.
    Robson H, Anderson E, Eden OB et al (1998) Chemotherapeutic agents used in the treatment of childhood malignancies have direct effects on growth plate chondrocyte proliferation. J Endocrinol 157:225–235CrossRefPubMedGoogle Scholar
  22. 22.
    Schwartz AM, Leonidas JC (1984) Methotrexate osteopathy. Skeletal Radiol 11:13–16CrossRefPubMedGoogle Scholar
  23. 23.
    Shalet SM, Beardwell CG, Pearson D et al (1976) The effect of varying doses of cerebral irradiation on growth hormone production in childhood. Clin Endocrinol 5:287–290CrossRefGoogle Scholar
  24. 24.
    Siebler T, Shalet SM, Robson H (2002) Effects of chemotherapy on bone metabolism and skeletal growth. Horm Res 58(Suppl 1):80–85CrossRefPubMedGoogle Scholar
  25. 25.
    Sklar C, Sarafoglou K, Whittam E (1993) Efficacy of insulin-like growth factor binding protein 3 in predicting the growth hormone response to provocative testing in children treated with cranial irradiation. Acta Endocrinol 129:511–515PubMedGoogle Scholar
  26. 26.
    Sklar CA, Mertens AC, Mitby P et al (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 87:3136–3141CrossRefPubMedGoogle Scholar
  27. 27.
    Sklar CA, Mertens AC, Walter A et al (2000) Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 35:91–95CrossRefPubMedGoogle Scholar
  28. 28.
    Thomas IH, Donohue JE, Ness KK et al (2008) Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer 113:3248–3256CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Weinstein RS, Jilka RL, Parfitt AM et al (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274–282CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Klinik für Allgemeine Kinderheilkunde, Hämatologie/Onkologie, Zentrum für Kinder- und JugendmedizinKlinikum Oldenburg, Medizinischer Campus Universität OldenburgOldenburgDeutschland
  2. 2.Klinik für Kinder- und Jugendmedizin, Pädiatrische Onkologie und HämatologieUniversitätsklinikum Schleswig-Holstein, Campus LübeckLübeckDeutschland
  3. 3.SPZ für chronisch kranke Kinder, Pädiatrische EndokrinologieCharité – Universitätsmedizin BerlinBerlinDeutschland

Personalised recommendations